Key result
Elevated troponin I in acute ischemic stroke predicts ~28-fold higher odds of poor discharge outcomes.
Why the study?
Stroke is a leading cause of death worldwide, and elevated cardiac troponin levels in stroke patients are associated with poorer prognosis.
Does elevated troponin I predict poor outcomes and in-hospital mortality in patients with acute ischemic stroke?
Observational (n=101)
No
Does elevated troponin I predict poor outcomes and in-hospital mortality in patients with acute ischemic stroke?
Effect estimate: OR 28.451 (95% CI 2.785-290.63)
p-value: p=0.005
Elevated troponin I during acute ischemic stroke is a strong independent predictor of poor functional outcomes and in-hospital mortality.
May aid risk stratification in acute ischemic stroke; hypothesis-generating pending prospective validation.
Background: Stroke is the second leading cause of death worldwide, comprising approximately 10% of all deaths. A substantial number of stroke patients have elevated cardiac troponin levels and are associated with poorer prognosis. Methods: This was a prospective observational study conducted for 1 year at Tribhuvan University Teaching Hospital, in which 101 acute ischemic stroke patients were enrolled. Data included vital signs, laboratory parameters, and clinical features evaluated at the time of admission. The National Institute of Health Stroke Scale (NIHSS) and modified Rankin scale (mRS) were used to assess stroke severity and outcomes. Results: Elevated troponin I (> 0.034 ng/mL) was observed in eight (7.9%) patients. Compared to patients with normal troponin I, patients with elevated troponin I were older(mean age 61vs 59.68 years), had higher blood glucose( 10.6 vs. 7.04 mmol/L), higher median white blood cells( 9.3 vs. 8.9 1,000/m3) and creatinine levels(119.5 μmol/L vs. 95.9 μmol/L), higher mean NIHSS scores on admission(16 vs. 8.6), and discharge(14.5 vs. 6.8), higher median mRS scores( 4.13 vs. 1.8) at discharge(p<0.001). Poor outcomes were observed in 34(33.66%) patients of 101 patients and death occurred in five (4.9%) patients. Patients with abnormal troponin I had poorer outcomes than normal troponin I level patients (p=<0.001) and significantly higher deaths (p=0.006). Univariate analysis of continuous variables revealed that patients with poor outcomes compared to good outcomes had higher troponin levels (0.029 vs. 0.013 ng/mL, p=0.001), creatinine levels (113.5 vs. 89.8μmol/L, p=0.007), NIHSS score on admission (13.4 vs. 5.10, p<0.001),discharge (12.4 vs. 5.1, p<0.001), and higher mRS scores at discharge (3.71 vs. 1.16, p<0.001).Multiple logistic regression analysis revealed that NIHSS score on admission>13(OR 15.902; 95%CI[3.65-69.28],p=<0.001) and abnormal troponin I level, troponin I>0.029 ng/mL (odds ratio[OR]:28.451; 95% CI[2.785-290.6],p=0.005) were significant predictors of poor outcomes. Significant predictor of in hospital mortality only included troponin I level >0.04 ng/mL (0R 0.071; 95% CI [0.005-1.037], P=0.05). Conclusion: Troponin I provide better information than age and other laboratory parameters in the prediction of outcomes of stroke. Elevation of troponin I during acute stroke is a strong predictor of both poor outcomes and in-hospital mortality.
No takes yet. Share an insight, caveat, or question.
Thapa et al. (2020) conducted an observational in Acute ischemic stroke (n=101). Elevated Troponin I (>0.029 ng/mL) vs. Normal Troponin I was evaluated on Poor outcomes (mRS > 2 at discharge) (OR 28.451, 95% CI 2.785-290.63, p=0.005). Elevated troponin I (>0.029 ng/mL) during acute ischemic stroke was a strong independent predictor of poor functional outcomes at discharge (OR 28.451).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: